Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2018-01-05
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group,
efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with
Type 2 Diabetes Mellitus with insufficient glycaemic control